SCHEMBL2567968

SCHEMBL2567968

O=C(Nc1ccc(OC(F)(F)F)cc1)Nc1cn(Cc2ccc(C(F)(F)F)cc2)c(C(=O)OCCO)n1

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 6/20 0.44
TRPV1 Q8NER1 1/20 0.43
PPARA Q07869 2/20 0.43
MAPT P10636 1/20 0.43
PKM P14618 1/20 0.43
XBP1 P17861 1/20 0.43
KMT2A Q03164 1/20 0.42
LMNA P02545 2/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
NAMPT P43490 2/20 0.40
FLT1 P17948 1/20 0.40
KDR P35968 1/20 0.40
EPHX1 P07099 1/20 0.39
P2RY1 P47900 1/20 0.39
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
MCHR1 Q99705 1/20 0.38
IGF1R P08069 1/20 0.38
FAAH O00519 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2879513 0.90 EPHX2 (0.54) EPHX2TRPV1PPARAMAPTPKM
SCHEMBL2567347 0.90 EPHX2 (0.41) EPHX2TRPV1PPARAMAPTPKM
SCHEMBL1595202 0.88 EPHX2 (0.51) EPHX2TRPV1PPARAMAPTPKM
SCHEMBL13197944 0.87 MCHR1 (0.43) EPHX2TRPV1PPARAMAPTPKM
SCHEMBL2561907 0.87 MCHR1 (0.46) EPHX2TRPV1PPARAMAPTPKM
SCHEMBL13197945 0.86 EPHX1 (0.41) EPHX2TRPV1PPARAMAPTPKM
SCHEMBL13197947 0.85 EPHX2 (0.39) EPHX2TRPV1PPARAMAPTPKM
SCHEMBL2565710 0.83 MCHR1 (0.46) EPHX2TRPV1PPARAMAPTPKM
SCHEMBL13197771 0.83 MCHR1 (0.43) EPHX2TRPV1PPARAMAPTPKM
SCHEMBL13206932 0.82 MCHR1 (0.42) EPHX2TRPV1PPARAMAPTPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1732901-B1 ANTIVIRAL 4-AMINOCARBONYLAMINO-SUBSTITUTED IMIDAZOLE COMPOUND AICURIS GMBH & CO KG (DE) 2011-11-02 EP disclosed
EP-1732901-B1 ANTIVIRAL 4-AMINOCARBONYLAMINO-SUBSTITUTED IMIDAZOLE COMPOUND AICURIS GMBH & CO KG (DE) 2011-11-02 EP disclosed
US-7767704-B2 Antiviral 4-aminocarbonylamino-substituted imidazole compounds AICURIS GMBH & CO. KG (DE) 2010-08-03 US disclosed
US-7767704-B2 Antiviral 4-aminocarbonylamino-substituted imidazole compounds AICURIS GMBH & CO. KG (DE) 2010-08-03 US disclosed
US-7767704-B2 Antiviral 4-aminocarbonylamino-substituted imidazole compounds AICURIS GMBH & CO. KG (DE) 2010-08-03 US disclosed
US-20080004275-A1 Antiviral 4-Aminocarbonylamino-Substituted Imidazole Compounds BAYER HEALTHCARE AG (DE) 2008-01-03 US disclosed
US-20080004275-A1 Antiviral 4-Aminocarbonylamino-Substituted Imidazole Compounds BAYER HEALTHCARE AG (DE) 2008-01-03 US disclosed
US-20080004275-A1 Antiviral 4-Aminocarbonylamino-Substituted Imidazole Compounds BAYER HEALTHCARE AG (DE) 2008-01-03 US disclosed
EP-1732901-A1 ANTIVIRAL 4-AMINOCARBONYLAMINO-SUBSTITUTED IMIDAZOLE COMPOUND Bayer HealthCare AG (DE) 2006-12-20 EP disclosed
WO-2005092865-A1 ANTIVIRAL 4-AMINOCARBONYLAMINO-SUBSTITUTED IMIDAZOLE COMPOUND BAYER HEALTHCARE AG (DE) 2005-10-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080004275-A1 Antiviral 4-Aminocarbonylamino-Substituted Imidazole Compounds IRF3, EIF2AK2, ZC3HAV1 EPHX2 3922/4885TRPV1 4838/4885PPARA 2490/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.